Hims & Hers Health (HIMS) CLO Soleil Boughton Sells 42,261 Shares

Soleil Boughton, the Chief Legal Officer at Hims & Hers Health, Inc. (HIMS), sold 42,261 shares of the company on June 15, 2026. This transaction was disclosed in a regulatory filing and took place on the open market. Unlike some executive trades that are scheduled months in advance, this specific sale was not conducted under a Rule 10b5-1 trading plan.

A Busy Month for Hims & Hers Insiders

The sale by Boughton was just one piece of a very active period for company leadership in June 2026. On the same day Boughton sold her shares, Chief Policy Officer Deborah Autor also sold 15,396 shares at an average price of $30.17, totaling roughly $464,497. However, the selling was balanced by significant buying from other executives. Chief Technology Officer Mohamed Elshenawy purchased 282,597 shares on June 15, and directors Delos Cosgrove and David Wells each bought 3,656 shares on June 11.

This isn't the only time Boughton has been active in the market recently. Later in the year, on October 14, 2026, she sold another 3,461 shares at $29.06 each, though that later trade was part of a pre-arranged 10b5-1 trading schedule. The mix of buying and selling among the top brass suggests different personal financial strategies even as the company continues to grow its revenue.

Hims & Hers Stock and Financial Performance

Shares of Hims & Hers Health were trading near $31.47 on Thursday. The stock has seen a wide range over the last year, moving between a low of $13.74 and a high of $57.45. It is currently trading just above its 50-day moving average of $29.40 and its 200-day moving average of $27.32, showing some steady support despite the distance from its yearly highs.

In its most recent financial reports, Hims & Hers showed strong top-line momentum with revenue of $2.58 billion and a growth rate of 38.2%. While the company is not yet profitable, reporting an EPS of -$0.64 and a net margin of -5.51%, investors often focus on its high revenue growth and a forward P/E ratio of 39.85. The company currently holds a debt-to-equity ratio of 477.13 and a current ratio of 0.93.

Analysts Set New Price Targets

Wall Street analysts have issued several updates following the company's recent performance. On August 24, 2026, Truist Securities maintained a Hold rating but raised its price target to $32.00. Earlier that month, Needham reiterated a Buy rating with a high price target of $42.00 on August 11. Other firms like Barclays and Citigroup have been more cautious; Barclays lowered its target to $35.00 on August 21, while Citigroup moved its target down to $33.00 on August 11.

Across 13 analyst opinions, the stock carries a consensus recommendation of Hold. The average price target of $31.15 is very close to where the stock is currently trading, suggesting that many experts believe the shares are fairly valued at these levels.

About Hims & Hers Health, Inc.

Hims & Hers Health runs a digital platform that connects patients with licensed healthcare providers for a variety of needs, from hair loss and skincare to mental health and weight loss. By selling both prescription and over-the-counter products directly to consumers online and through retail partners, they have built a brand focused on making healthcare feel more like a modern consumer experience. The company’s ability to scale this model is a key factor for the insiders who are currently buying and selling shares.

Investors will likely watch the next earnings report scheduled for November 9, 2026, to see if the company can narrow its losses. While insider sales like Boughton's are backward-looking and often reflect personal financial planning, the combined activity of the board and executive team provides a window into how leadership views the company's valuation during a period of rapid expansion.